Biogen (NASDAQ:BIIB) reported quarterly earnings of $3.44 per share which beat the analyst consensus estimate of $3.35 by 2.69 percent. This is a 16.61 percent increase over earnings of $2.95 per share from the same period last year. The company reported quarterly sales of $2.46 billion which beat the analyst consensus estimate of $2.40 billion by 2.17 percent. This is a 2.89 percent increase over sales of $2.39 billion the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。